Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. reported first-half 2026 revenue of RMB 866 million, up 34.84% year on year, while net profit attributable to shareholders of the parent company rose 95.10% to RMB 371 million. Non-GAAP net profit attributable to the parent increased 65.15% to RMB 260 million, basic earnings per share climbed 95.24% to RMB 0.41, and research and development expenses rose 32.41% to RMB 245 million. The company proposed an interim cash dividend of RMB 0.42 per 10 shares, tax included, without issuing bonus shares or converting capital reserves into share capital. Sunshine Guojian received approval for Yisaituo (development code 608) in moderate-to-severe plaque psoriasis and Yisaina (development code 613) for specified adult acute gouty arthritis flares. Its carte qibart injection program, development code 611, had its application for adult moderate-to-severe atopic dermatitis accepted in February. Multiple Phase III trials reached enrollment or efficacy milestones, while earlier programs targeting lupus, ulcerative colitis and atopic dermatitis also progressed. The Pfizer-partnered PF-08634404, or SSGJ-707, program has launched nine global multicenter trials in solid-tumor indications including non-small cell lung cancer and colorectal cancer. Sunshine Guojian said its pipeline is developing into a tiered portfolio of commercial products, medium-term growth programs and longer-term innovation reserves, supported by a commercialization network covering nearly 4,800 medical institutions.